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ABSTRACT
BACKGROUND: The most common factor associated with poor control of 
hypertension is treatment nonadherence to antihypertensive drug therapy. 
OBJECTIVE: To measure drug nonadherence and associated factors in 
pharmacologically treated hypertensive patients.
METHODS: A prospective observational study was carried out from March 
2007 to August 2009 at a community pharmacy in Spain. A pharmacist invit-
ed a convenience sample of hypertensive patients aged 50 years and older 
taking antihypertensive medication for at least 3 months prior to participate 
in the study. Drug nonadherence was analyzed by 3 separate methods: pill 
count, as the gold standard method, and Haynes-Sackett and Morisky-Green 
questionnaires. A descriptive analysis of drug nonadherence and variables 
associated with nonadherence was performed. Logistic regression models 
were used to determine the variables associated with nonadherence.
RESULTS: Data were recorded from 419 patients. The drug nonadherence  
ratio varied depending on the method used: 62.8% by pill count, 3.1% 
by the Haynes-Sackett self-report test, and 36% according to the 
Morisky-Green test. In the multivariate model, the variable associated 
with a decrease in drug nonadherence was years of known hypertension 
(OR = 0.962, 95% CI = 0.937-0.988), and the variables associated with 
an increase in drug nonadherence were loose-pill combination therapy 
versus fixed-dose combination therapy or monotherapy (OR = 4.099, 95% 
CI = 2.494-6.757) and good perception of quality of life (OR = 1.276, 95% 
CI = 1.109-1.471).
CONCLUSIONS: The magnitude of drug nonadherence varies depending on 
the method of measurement. The pill count method (reference method) 
revealed that 2 out of 3 patients with hypertension did not have good 
adherence. This study highlights the lack of antihypertensive drug adher-
ence and the pharmacist’s ability to detect the associated factors in order 
to find the best way to deal with nonadherence.
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RESEARCH
Arterial hypertension is one of the leading causes of morbidity, mortality, and disability in the world.1 More than 74.5 million Americans have hypertension, with 
an estimated cost of $76.6 billion per year.2 The prevalence 
of hypertension in Spain is high, approximately 30%-50% 
(47% men, 39% women), and it increases with age (comparing 
groups aged 35-44 years vs. aged 65-75 years, 24% vs. 72% in 
men and 12% vs. 72% in women).3,4
Hypertension control is an issue of great concern, and 
while it has improved, that improvement is still insufficient, 
around 50%,4 and one of its ramifications is loss of quality 
of life (QoL).5,6 The most important factor associated with 
poor control of hypertension is treatment nonadherence. The 
World Health Organization (WHO) estimates that 50%-70% of 
people do not take their antihypertensive medications as pre-
scribed.7 The magnitude of antihypertensive drug nonadher-
ence in Spain ranges from 7.1%-66.2%, according to reviews by 
Puigventós et al. (1997) and Márquez et al. (2006).8,9
Numerous methods are used to assess patient compliance. 
Indirect measures of adherence are simple and economical, 
and they include various forms of self-reporting by the patient, 
such as medication measurement (pill count), compliance tests 
(Morisky-Green, Haynes-Sackett),10,11 use of electronic moni-
toring devices, and review of prescription records and claims. 
Pill count is considered the “gold standard” for measuring 
medication adherence.12 The Morisky-Green and the Haynes-
Sackett tests are most often used in clinical practice because of 
their high specificity, simplicity, and brevity.
• The most important factor associated with poor control of hyper-
tension is treatment nonadherence. 
• The World Health Organization estimates that 50%-70% of people 
do not take their antihypertensive medications as prescribed. The 
magnitude of antihypertensive drug nonadherence in Spain ranges 
from 7.1%-66.2%, and it is difficult to identify associated factors.
• The role of the pharmacist in the assessment of therapeutic 
adherence has been recognized.
What is already known about this subject
• The magnitude of therapeutic nonadherence is important because 
2 out of 3 hypertensive patients in the study who visited the 
pharmacy were identified as noncompliant with antihypertensive 
drug therapy.
•	Antihypertensive therapy complexity and perception of a good 
quality of life were the variables associated with higher nonadher-
ence; years of known hypertension was the variable associated 
with lower nonadherence.
• The magnitude of drug nonadherence varies depending on the 
method of measurement: pill count (62.8%), Haynes-Sackett test 
(3.1%), and Morisky-Green test (36%).
What this study adds
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Process
Once patients were recruited, the initial visit and 2 follow-up 
visits were made. At the initial visit for each patient, a Case 
Report Form listing anthropometric characteristics, dietary 
habits, exercise, smoking, alcohol intake, and comorbidities 
was recorded. In addition, BP was measured in both arms, and 
the second visit was planned in 2-3 days by asking the patient 
to come back with all medications he or she had at home (not 
only for hypertension) to avoid mistakes, since some patients 
were not able to identify all medications for hypertension. The 
duration of the first visit was about 30 minutes. In the second 
visit, the medications were reviewed by counting the pills for 
each hypertensive medication that the patient had at home 
(count 1). BP was measured on the arm where BP was higher 
when it was measured initially, and the European Quality of 
Life (EuroQOL) test was completed.15 The duration of the sec-
ond visit was about 45 minutes. The third and final visit was 
planned in 30 days from the second visit. In the third visit, the 
medications were reviewed by counting the pills for each anti-
hypertensive medication that the patient had at home (count 2). 
BP was measured on the arm where BP was higher when mea-
sured at visit 1; a blood sample was taken for analytical vari-
ables; and the patient was asked about any new prescriptions 
or therapeutic changes in medication for hypertension (HTN). 
The patient was excluded if any change in the HTN medica-
tion had been made between the second and third visits. The 
Haynes-Sackett16 and Morisky-Green17 tests were then admin-
istered. The duration of the last visit was about 60 minutes.
Measurements
The study variables were as follows:
•	 Lifestyle: Salt consumption, smoking habit, alcohol con-
sumption, and sedentary lifestyle. Salt consumption was 
defined as high if it was more than 5 grams per day (gm/
day). Smoking was defined as regular consumption of any 
kind of tobacco. Alcohol consumption was defined as tak-
ing more than 30 gm/day in men and 20 gm/day in women. 
Sedentary lifestyle was defined as an exercise (e.g., walking) 
less than 30-45 minutes 3-5 days a week.18-20
•	 Demographic and anthropometric characteristics: Age, sex, 
weight, height, and body mass index (BMI).18
•	 Comorbidity: Diabetes, dyslipidemia, metabolic syndrome, 
obesity, cardiovascular risk, HTN, and other chronic dis-
eases (e.g., chronic obstructive pulmonary disease, heart 
failure, atrial fibrillation, ischemic heart disease, depres-
sion). Comorbidity variables were measured according to a 
patient interview and medication prescribed. Metabolic syn-
drome and cardiovascular risk were calculated according to 
Spanish and European guidelines.21-23 Obesity was defined 
as a BMI > 30 kilogram per squared centimeter.18 
•	 BP measurement: Mean systolic BP and mean diastolic BP. 
BP was measured 4 times (spaced 2 minutes apart) on 
Adherence is a complex process, and nonadherence has 
often been poorly defined. Patients’ decisions about how to 
manage their medications are likely based on economic, physi-
cal, psychological, and social considerations.13 Identifying fac-
tors associated with adherence would be of value for health 
care providers in order to focus on strategies to enhance patient 
adherence to antihypertensive medications. Given the magni-
tude of nonadherence and its complexity, an interdisciplinary 
approach involving the pharmacist could add value to the 
overall treatment of patients. This interdisciplinary approach 
is a recommendation made by the WHO, the American 
Society of Hypertension, and the International Pharmaceutical 
Federation.7,14
The purpose of this study was to measure adherence to anti-
hypertensive medications assessed by a community pharmacist 
and to identify factors associated with nonadherence. The pri-
mary objective was to determine the extent of medication non-
adherence in pharmacologically treated hypertensive patients 
who visited a specified community pharmacy. Secondarily, we 
identified associated factors of nonadherence to antihyperten-
sive medications, such as sociodemographic and anthropomet-
ric characteristics, comorbidity, QoL, hypertensive and con-
comitant medication, years of known hypertension, and other 
general factors associated with therapeutic nonadherence.
■■  Methods
Scope, Study Period, and Recruitment
This study was carried out in a community pharmacy in Petrer 
(Alicante) in southeastern Spain. The study design, data col-
lection, and analysis took place between March 3, 2007, and 
August 14, 2009. This was an observational prospective study 
that used consecutive nonprobability sampling. The sample 
size was calculated, estimating the rate of nonadherence as 
50%, at a sampling precision level of ± 4.5% and 95% confi-
dence interval (CI). Assuming a loss to follow-up of 8%, at least 
418 patients were needed.
As patients visited the pharmacy to collect their antihyper-
tensive medications or to measure their blood pressure (BP), the 
community pharmacist explained the study to patients who met 
the inclusion criteria and invited them to participate. Patients 
included were hypertensive patients aged 50 years or older who 
were taking antihypertensive medication for at least 3 months 
and who visited the pharmacy during the study period and gave 
their informed consent to participate in the study. 
Patients were excluded if they presented with dementia or 
severe diseases or any mental, pathological, or social issue 
that could prevent adequate completion of the data collection 
notebook or pill count. Also excluded were pregnant women, 
participants in other research studies, persons living with 
somebody else taking the same antihypertensive treatments, 
anyone with treatment distributed over several locations, and 
anyone who did not have a telephone contact number.
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each of the 3 visits using an Omron 705 CPII automated 
oscillometric upper arm sphygmomanometer, which was 
validated and calibrated in accordance with the protocols of 
the Spanish and European clinical practice guidelines.21-23 
BP was taken according to the Spanish and European guide-
lines: 5 minutes at rest, back supported with feet flat on the 
floor; proper cuff size at heart level; refrain from drinking 
coffee or tea, smoking, or exercise at least 30 minutes prior 
to measurement. The average BP was obtained from the 
third visit, when white coat syndrome was reduced.24 The 
patients came in the morning fasting and without taking 
their antihypertensive medications in order to avoid the 
immediate effect of the pill. According to the European 
clinical practice ESH/ESC 2007 guidelines, BP control was 
defined as systolic BP (SBP) < 140 millimeters of mercury 
(mmHg) and diastolic BP (DBP) < 90 mmHg for patients 
without diabetes, cardiovascular disease, or chronic kid-
ney disease (CKD) and of SBP < 130 mmHg and DBP < 80 
mmHg for patients with diabetes or CKD.23 
•	 Quality of life: QoL was determined using the EuroQol-5D 
(EQ-5D)health questionnaire.15 The EQ-5D measures the 
QoL of patients in 5 dimensions (mobility, self-care, daily 
activities, pain/discomfort, and anxiety/depression), each 
with 3 levels of severity (no problems [1], some problems [2], 
many problems [3]) where the minimum score is 5 (good 
QoL) and the maximum score is 15 (very poor QoL). The 
patients were subsequently categorized into 2 categories: 
(1) Good QoL—those with better scores in EuroQol-5D (5 
points), which stands for no problems in every 5 dimen-
sions—and (2) Poor QoL—the remaining patients who 
scored worse, for higher than 5 points.
•	 Therapeutic nonadherence: Three indirect methods were used 
to measure nonadherence.
1. Pill count. Initial pill count required the patients to bring 
their antihypertensive medications in their packaging. At 
the second and third visits, the pharmacist recorded the 
date and the number of tablets in each patient’s posses-
sion. Thereafter, the number of tablets consumed from 
the initial count was calculated. For those cases in which 
the patient received additional packs of antihypertensive 
drugs, the new tablets were added to the initial count. 
The number of tablets that the patient should have con-
sumed in the time between the 2 counts was calculated 
(number of days multiplied by the number of tablets 
prescribed per day). Finally, the percentage of adherence 
by the patient was calculated as follows: 
Percentage      Number of tablets consumed 
of Adherence = 
__________________________  × 100
Number of tablets that 
should have been consumed 
Following Haynes et al. (1980),16 drug nonadherence 
was established as taking less than 80% of the prescribed 
pills. If the patient was taking multiple antihypertensive 
medications, the average percentage of adherence for every 
antihypertensive medication that the patient was taken at 
that moment was calculated.
In addition, at the final third visit, 2 more methods based 
on clinical interview were used: the Haynes-Sackett16 and 
Morisky-Green17 tests. In order to compare validity of each 
method, sensitivity, specificity, and predictive values were 
calculated by using pill count as the gold standard method. 
2. Haynes-Sackett test.16 This is a self-reported test that asks 
the following question: “People often have difficulty tak-
ing their pills for one reason or another and we are inter-
ested in finding out any problems that occur so that we 
can understand them better.” Patients were then asked 
whether they ever missed their pills and, if so, the patient 
was considered nonadherent to treatment. 
3. Morisky-Green test.17 This is a self-reported test that asks 4 
questions: (a) Have you ever forgotten to take your medi-
cine? (b) At times, are you not careful about taking your 
medicine? (c) When you feel better, do you sometimes 
stop taking your medicine? (d) At times, if you feel worse 
when you take your medicine, do you stop taking them? 
Patients were considered nonadherent if they responded 
affirmatively to at least 1 question.
•	 Antihypertensive therapy complexity: Monotherapy (MONO) 
was defined as a treatment with a single drug; antihyper-
tensive fixed-dose combination therapy (FDCT) was defined 
as a formulation including 2 or more active pharmaceutical 
ingredients combined in single dosage form, which is manu-
factured and distributed in certain respective fixed doses; 
and loose-pill combination therapy (LPCT) was defined as 
patients taking 2 or more active pharmaceutical ingredients 
separately, not in single dosage form.
Statistical Analysis
We performed a descriptive assessment of all variables included 
in the study. After determining the normality of the variables 
with the Kolmogorov-Smirnov test, the Student’s t-test or 
Mann-Whitney test, as appropriate, was used to compare the 
means. The multiple comparisons of means were performed 
using analysis of variance (ANOVA) or the Kruskal-Wallis test. 
Correlation of quantitative variables was performed by calcu-
lating the Pearson’s or Spearman’s correlation coefficient. The 
association between qualitative variables was carried out using 
the chi-square statistic (X2). Logistic regression models were 
carried out to determine the variables associated with nonad-
herence, taking into account those independent variables with 
significance in the bivariate analysis. The goodness of fit of the 
final model was checked out. The statistical analysis was done 
using IBM SPSS Statistics 19.0 (SPSS, Inc., Chicago, IL).
The project was approved by the Hospital Ethics Committee 
of the Department of Elda (Alicante, Spain), ensuring informa-
tion confidentiality according to the Spanish Data Protection 
Law (15/1999).25
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■■  Results
A total of 419 patients were recruited. Figure 1 shows rea-
sons why some patients were excluded and reasons for with-
drawal. The baseline participation characteristics of patients 
are described in Table 1. 
Measurement of Nonadherence
According to pill count, 62.8% (95% CI = 58.2-67.4) of the 
hypertensive patients were nonadherent (Figure 2). Only 
3.1% (95%, CI = 1.4-4.8) of the hypertensive patients reported 
nonadherence on the Haynes-Sackett self-report test (HST). 
According to the Morisky-Green test (MGT), 36% (95% 
CI = 31.4-40.6) were considered nonadherent. In Table 2, the 
methods of measurement (HST, MGT) are compared with the 
reference test (pill count). The sensitivity of HST is very poor 
(3%), as the specificity is very high (97%). The MGT has low 
sensitivity (36%) and slightly high specificity (63%), but both 
validity indexes are lower than 80%, a target to consider as a 
good index for screening.
Variables Associated with Nonadherence
According to the bivariate analysis of the study variables with 
pill count in the range of poor adherence < 80% and good 
adherence > 80%, there was a greater proportion of patients 
with nonadherence that had (a) cardiovascular risk (CVR) 
≥ 20%, (b) 5 or more medications, (c) HTN therapy with LPCT, 
(c) more than 1 pill for HTN, and (d) a good perception of QoL. 
These variables were statistically significant (P < 0.05). 
Invited to participate 
N = 500
Completed study 
(3 visits)
N = 419
Withdrew from 
study 
N = 58
Only 1 visit 
N = 32
Only 2 visits 
N = 16
Subject failed to 
follow protocol 
N = 10b
Included 
N = 477
Excluded 
N = 23a
FIGURE 1 Study Participants
aReasons for exclusion (n = 23): declined to participate (n = 7); patients with 
dementia or severe diseases or any mental, pathological, or social issues that could 
prevent adequate completion of data collection notebook or pill count (n = 7); par-
ticipants in other research studies (n = 1); persons living with somebody else taking 
the same antihypertensive treatments (n = 5); anyone with treatment distributed 
over several locations (n = 2); and anyone who did not have a telephone contact 
number (n = 1). 
bReasons for failing to follow protocol (n = 10): not bringing all antihypertensive medi-
cations that patient is taking (n = 8) and changes in antihypertensive drugs (n = 2).
Variables Total (n = 419) 95% CI
Age (years), mean (SD)  64.7 (12.4) 63.4-65.8
Women, n (%)  235 (56.1) 51.3-60.9
BMI (kg/m2), mean (SD)  31.3 (5.4) 30.8-31.8
Total drugs, mean (SD)  4.7 (2.7) 4.4-4.9
Total pills, mean (SD)  4.9 (3.8) 4.6-5.3
Lifestyle, n (%)
Salt consumption > 5 gm/day  326 (77.8) 73.8-81.8
Smoking habit  51 (12.2) 9.4-15.7
Alcohol consumption > 40 gm/day 
(men) or 23 gm/day (women)
 14 (3.3) 2.0-5.5
Exercise (less than 30-45 min/ 
3-5 days/week)
 189 (45.10) 40.3-49.9
Comorbid conditions, n (%)
Diabetes  92 (22.0) 18.0-26.0
Dislipidemia  139 (33.2) 28.7-37.7
Metabolic syndrome (ATPIII guideline)  230 (54.9) 50.1-59.7
Obesity (BMI > 30)  229 (54.7) 49.9-59.5
High CV risk ( ≥ 20%)a  293 (69.9) 65.5-74.3
Patients with 2 or more chronic 
conditions, n (%)
 369 (88.1) 85.0-91.2
Blood pressure 
Patients with good control, n (%)b  112 (26.7) 22.5-30.9
Systolic blood pressure, mean (SD)  142.3 (21.6) 140.2-144.4
Diastolic blood pressure, mean (SD)  80.2 (10.1) 79.9-81.1
Evolution of HTN (years)  9.7 (8.9) 8.8-10.5
Total HTN drugs, mean (SD)  1.6 (0.9) 1.5-1.7
Total HTN pills, mean (SD)  1.6 (1.0) 1.5-1.7
Total HTN active agentsc  1.8 (1.0) 1.8-1.9
Quality of life, n (%)
Good quality of life (5 points in 
EuroQol-5D test) 
 137 (32.0) 28.2-37.2
Nonadherence, n (%)
Nonadherence, pill count < 80%  263 (62.8) 58.2-67.4
Nonadherence, Haynes-Sackett test  13 (3.1) 1.4-4.8
Nonadherence, Morisky-Green test  151 (36.0) 31.4-40.6
Antihypertensive therapy complexity, n (%)
Monotherapy  185 (44.2) 39.4-49.0
Fixed-dose combination therapy  69 (16.5) 12.9-20.1
Loose-pill combination therapy  165 (39.4) 34.74-44.1
aHigh CV risk according to ESH/ESC 2007 guidelines.23 
bGood HTN control according to ESH/ESC 2007 guidelines: systolic blood pressure 
<140 mmHg and diastolic blood pressure < 90 mmHg. For diabetes, CV disease, 
and chronic kidney disease, systolic blood pressure < 130 mmHg and diastolic blood 
pressure <80 mmHg. 
cSome drugs can contain 2 or more active agents. 
ADP III = Adult Treatment Panel; BMI = body mass index; CI = confidence interval;  
CV = cardiovascular; ESH/ESC = European Society of Hypertension/European 
Society of Cardiology; EuroQoL = European Quality of Life; gm/day = gram per 
day; HTN = hypertension; kg/m2 = kilogram per square meter; min = minute; 
mmHg = millimeter per mercury; SD = standard deviation.
TABLE 1 Baseline Participation Characteristics
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According to the bivariate analysis of the association of 
quantitative variables with nonadherence as measured by pill 
count (nonadherence criterion < 80%), there was a greater 
proportion of patients with nonadherence taking more medi-
cations for HTN in terms of number of pills and/or number of 
active agents.
Multivariate Model
The model was highly significant (P < 0.001), explaining 15.7% 
of variability. After adjusting for other confounders, 3 variables 
were found associated with nonadherence (Table 3): 
•	 The	years	of	known	HTN	(P = 0.005) decreased nonadher-
ence (odds ratio [OR] = 0.962, 95% CI = 0.937-0.988).
•	 HTN	 therapy	 with	 LPCT	 (P < 0.001) increased nonadher-
ence. Thus, taking a greater number of pills for HTN 
increased nonadherence (OR = 4.099, 95% CI = 2.494-6.757).
•	 Good	perception	of	QoL	(P = 0.001) increased nonadherence 
(OR = 1.276, 95% CI = 1.109-1.471).
■■  Discussion
The characteristics of the patient sample in our study indi-
cated that patients had a mean age of 64 years, with a slight 
predominance of women and with coexisting CVR factors. The 
predominant cardiovascular factors were obesity, dyslipidemia, 
diabetes, physical inactivity, metabolic syndrome, and a high 
CVR. These factors are consistent with other studies conducted 
in Spain.26-29 Most of the subjects were polymedicated patients 
with multiple chronic pathologies. In our study, patients with 
high CVR, who require more BP control, had a high percent-
age of antihypertensive treatment using MONO (44.2%) and a 
low percentage using FDCT (16.5%). Nevertheless, guidelines 
advise prescribing a combination of drugs and in FDCT, for 
patients with high CVR, since simplification of treatment pro-
motes adherence.22,23,30,31
In our study, 32% of patients perceived an acceptable QoL, 
and this perception is associated with nonadherence. This 
could be because these patients did not perceive the vascu-
lar risk they have, since HTN is asymptomatic. So, strategies 
involving motivation, information, and developing attitudes 
such as active participation in self-monitoring and in disease 
treatment should be considered.5
Prevalence of Nonadherence
Based on the pill count method, almost 2 out of 3 hypertensive 
patients in our study failed to comply with drug treatment. In 
considering our results, we look to Haynes et al.,16 who coined 
the “rule of thirds” in chronic medication, which states that a 
third takes medication regularly, a third sometimes, and a third 
almost never. Nevertheless, other Spanish studies have found a 
lower proportion of nonadherence. Puigventós et al.8 measured 
53.6% nonadherence by pill count; Márquez et al.9 also mea-
sured by pill counts or medication event monitoring system 
(MEMS) and found 32.53% nonadherence. Other studies such 
as Puras et al. (2001)32 found 55.2% nonadherence, close to 
that obtained in our study, and Garcia Navarro et al. (2001)33 
found a nonadherence rate of 40%. In community pharmacy, 
the study by Bofil et al. (2006)34 stands out, with a nonadher-
ence rate of 49%, as well as the study by Fikri-Benbrahim 
et al. (2013)35 with a rate of 13.5%. In addition, Baena-Díez 
et al. (2011)36 found a nonadherence rate of 51.3% using the 
prescription register (95% CI = 44.3%-58.3%) and 15.4% (95% 
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FIGURE 2 Extent of Nonadherence in Patients 
with HTN Treated with Drugs Based 
on 3 Measurement Methods
HTN = hypertension.
Pill Count
TotalNonadherence Adherence
Haynes- 
Sackett, 
n (%)
Nonadherence  8 (3.0)  5 (3.2) 13
Adherence  255 (97.0)  151 (96.8) 406
Total  263 (100.0)  156 (100.0) 419
Note: Sensitivity = 0.03; specificity = 0.97; positive predictive value = 0.62; and nega-
tive predictive value = 0.37.
Kappa Index = -0.001 (95% CI = 0.076-0.074); poor concordance; chi square = 0.01, 
P = 0.92.
Pill Count
TotalNonadherence Adherence
Morisky- 
Green, 
n (%)
Nonadherence  94 (35.7)  57 (36.5) 151
Adherence  169 (64.3)  99 (63.5) 268
Total  263 (100.0)  156 (100.0) 419
Note: Sensitivity = 0.36; specificity = 0.63, positive predictive value = 0.62; and nega-
tive predictive value = 0.37.
Kappa Index = -0.007 (95% CI = 0.096-0.082); poor concordance; chi square = 0.03, 
P = 0.86.
CI = confidence interval.
TABLE 2 Comparison of Different Methods for 
Measuring Nonadherence
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problem must be recognized in clinical practice. Interventions 
to improve therapeutic adherence are needed that involve not 
only physicians and nurses but pharmacists as well. 
Factors Associated with Nonadherence
The most important factor seen to be related to nonadherence 
was therapeutic complexity.50 Although there is great variabil-
ity in the factors identified in different studies, there is no 1 
set of variables that completely explains the high percentage of 
nonadherence. 
When performing multivariate analysis, it is noteworthy 
that very few variables fit the model. Only 3 variables were 
highly significant in our study (Table 3). The number of years 
of known HTN was negatively associated with nonadherence, 
as more years of HTN diminishes nonadherence. Another 
study found that length of HTN diagnosis was directly associ-
ated with nonadherence.51 Another found that, for men, shorter 
length of stay was negatively associated with nonadherence 
(OR = 0.16, 95% CI = 0.05-0.57), and no association between 
length of stay and nonadherence was found for women.52
A variable positively associated with nonadherence was 
having a good perception of QoL. Perhaps people with good 
QoL perception are less aware of the disease. Previous studies 
assessing the relationship between QoL perception and medi-
cation adherence have produced different results, which may 
be due to variation in the techniques used to measure QoL 
and the study populations examined.53-55 Further research is 
needed to understand the mechanisms that affect adherence to 
antihypertensive medications.
HTN therapy with LPCT increased nonadherence. 
Thus, taking a greater number of pills for HTN increased 
nonadherence. So, simplification of drug regimen, that is, 
CI = 10.3%-20.4%) when using the Morisky-Green test.17 It 
should be noted that some of these were intervention studies, 
and different methodological approaches were used. These fac-
tors could explain the different results of drug nonadherence 
prevalence obtained.
Outside Spain, other studies reported similar data to those 
found in our study. According to the 2011 NICE Guidelines,37 it 
was estimated that between 50%-80% of patients with HTN do 
not take all their prescribed medications. Other studies (Table 
4) show varying results, from 7.5% to 91%.16,38-50 These study 
periods range from the late 1970s to the 2000s, and the meth-
odologies used include pill count and other MEMS. 
The variation seen in these studies relates to differences in 
study groups, duration of follow-up, and drug regimens used 
in different studies. Another source of variation that could 
explain the differences in rates of adherence is the method used 
to measure adherence. Examples of methods used include cal-
culating percentage of pills taken in a specific time period, per-
centage of patients taking 80% of their pills, improvement in 
number of pills taken, dropouts from treatment and follow-up, 
and missed appointments.7 Nevertheless, in most of these stud-
ies, nonadherence for HTN medications is very high, and this 
Variable Adjusted OR 95% CI P Value
Sex
Male Reference
Female 1.46 0.95-1.97 0.140
Age 1.02 51.30-60.90 0.059
Evolution of HTN (years) 0.96 0.94-0.99 0.005
CV risk (> 20%) 1.09 0.73-1.46 0.625
Metabolic syndrome 1.43 0.90-1.96 0.185
BMI (> 30 kg/cm2) 1.00 0.96-1.05 0.959
Diabetes mellitus 1.22 0.62-1.83 0.510
Dyslipidemia 1.15 0.59-1.72 0.616
SBP (> 140 mmHg) 0.99 0.98-1.01 0.416
DBP (> 90 mmHg) 1.03 1.00-1.06 0.026
Total drugs 0.90 0.75-1.06 0.229
Total pills 0.96 0.86-1.07 0.489
Total drugs for HTN 1.01 -0.46-2.48 0.989
Total pills for HTN 1.17 0.57-1.78 0.604
Total active agents for HTN 1.11 0.18-2.04 0.826
HTN treatment
Fixed-dose combination therapy Reference
Loose-pill combination therapy 4.09 2.50-6.80 < 0.001
Number of diseases 1.03 0.99-1.07 0.942
Good QoL (5 points in EuroQol-5D) 1.28 1.11-1.47 0.001
BMI = body mass index; CI = confidence interval; CV = cardiovascular; DBP = dia-
stolic blood pressure; EuroQol = European Quality of Life survey; HTN = hyperten-
sion; kg/m2 = kilogram per cubic meter; mmHg = millimeter of mercury; OR = odds 
ratio; QoL = quality of life; SBP = systolic blood pressure.
TABLE 3 Multivariate Logistic Regression 
Analysis to Assess Variables 
Associated with Nonaderence to 
Antihypertensive Drug Therapy Author Year of Publication
Nonadherence 
Percentage
Sackett38 1975 45%
Logan39 1979 51%
Haynes16 1980 33%
Enlund41 1982 33%
Lim42 1992 26%
Mounier-Vehier44 1998 7.5% (MEMS)
Guo43 2001 36.6%
Baulmann40 2002 50% (MEMS)
Schroeder50 2004 30%-50% 
Lee45 2006 38.8%
Corrao46 2008 50% at 5 years
Vrijens47 2008 50% at 1 year
Mazzaglia48 2009 91.9% at 6 months
Morgado49 2011 21%-42%
HTN = hypertension; MEMS = medication event monitoring system.
TABLE 4 Quantification of Drug Nonadherence 
in HTN in International Studies
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to the ideal method is pill count.12,60 This method requires 
more effort because several visits are needed, which is why 
this method is less often used than others. In our study, 1 per-
son conducted the interviews to minimize bias from different 
observers.
Another information or measurement bias is failure by the 
patient to provide all the requested medications. Patients were 
asked to bring all medications that they were taking. We asked 
about any forgotten medication, inviting them to bring it after 
the visit or calling them at home after the visit to avoid losses. 
Eight subjects failed to bring all antihypertensive medications 
or were impossible to contact by phone (Figure 1). 
■■  Conclusions
The magnitude of therapeutic nonadherence is important 
because, based on the pill count method, 2 out of 3 hypertensive 
patients (62.8%) who visit the pharmacy are identified as non-
compliant with antihypertensive drug therapy. Based on other 
methods, this proportion changed significantly—36.0% with 
the Morisky-Green test and 3.1% with the Haynes-Sackett test. 
Few variables are associated with therapeutic nonadher-
ence: the use of LPCT, perception of a good QoL, and less years 
of known HTN. Therapeutic adherence might be improved if 
the causes are identified. This study shows that in addition to 
physicians and nurses, pharmacists are able to provide infor-
mation that can better help us to understand nonadherence. 
Thus, we should use all avenues available to us in order to deal 
with the issue of nonadherence.
using FDCT will be associated with good adherence. This is 
consistent with the revision by Schroeder et al. (2004)50 and 
with the study by Sicras Mainar et al. (2011).56 In a systematic 
review, Claxton et al. (2001)57 stated that more frequent dos-
ing was associated with lower adherence rates. Adherence 
was significantly higher for once-daily versus 3-times-daily 
(P = 0.008), once-daily versus 4-times-daily (P < 0.001), and 
twice-daily versus 4-times-daily regimens (P = 0.001). The 
2013 ESH/ESC Guidelines58 favor the use of combinations of 2 
antihypertensive drugs at fixed doses in a single tablet because 
reducing the number of pills to be taken daily improves adher-
ence and increases the rate of BP control. Other variables such 
as comorbidity and gender were not associated with adherence.
Studies undertaken to investigate variables influencing 
treatment adherence have not been able to identify a clear 
profile of the noncompliant patient, showing differences 
between studies.50,59,60 It has been noted that this profile may 
change over the therapeutic life of the hypertensive patient 
because of external circumstances (personal, familiarity, job, 
social). In our study, it has been shown that the prevalence of 
therapeutic nonadherence in hypertensive patients could vary 
widely, depending on the method that has been used, which 
has implications for clinical practice. In our study, the meth-
ods were chosen according to their validity and applicability. 
Variation between diagnostic methods is usual because some of 
them have high specificity (few false positives), and others have 
high sensitivity (few false negatives). In clinical practice, they 
should be combined.
This study shows that pharmacists can provide information 
about the causes of nonadherence, which is a first step in deal-
ing with the nonadherence problem. A further step would be 
pharmacists working together with physicians and nurses in 
order to improve therapeutic adherence. 
Limitations
This study was conducted in a community pharmacy using 
patients who go to the pharmacy to collect their medications or 
to measure their BP. A consecutive population sample instead of 
a random sample from a list of patients may involve a popula-
tion selection bias. However, the characteristics of the sample 
correspond to those usually found in such studies, so no bias 
was observed in age, sex, or HTN characteristics.4,36 Another 
potential bias could be that patients who choose not to follow 
their prescriptions after leaving their physicians’ offices do not 
go to the pharmacy to collect their medications. If these patients 
were included, the proportion of noncompliant patients would 
be even higher than that found in this study. On the other hand, 
during the pill count process, patients may feel they are being 
studied (Hawthorne effect) and become more compliant. 
There is no perfect method to measure nonadherence. 
Questionnaires and clinical interviews are widely used for 
measuring adherence, some with low validity, but the closest 
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